Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 2, 2002 - Issue 6
Submit an article Journal homepage
19
Views
1
CrossRef citations to date
0
Altmetric
Drug Evaluation

Clomipramine use in obsessive–compulsive disorder

Jennifer L Ivey Department of Psychiatry, Wayne State University School of Medicine, UPC-Jefferson, 2751 East Jefferson Avenue, Detroit, MI 48207, USA. [email protected]
&
David R Rosenberg Department of Psychiatry, Wayne State University School of Medicine, UPC-Jefferson, 2751 East Jefferson Avenue, Detroit, MI 48207, USA. [email protected]
Pages 783-790 | Published online: 10 Jan 2014

References

  • Robins LN, Helzer JI, Weissman MM eta]. Lifetime prevalence of specific psychiatric disorders in three sites. Arch. Gen Psychiatry 41, 949–958 (1984).
  • Flament NE, Whitaker A, Rapoport JL. Obsessive compulsive disorder in adolescence: An epidemiological study. Am. Acad. Child Adolescent PTchiatry27, 764–771 (1988).
  • Hanna GL. Demographic and clinical features of obsessive-compulsive disorder in children and adolescents. jAm Acad. Child Adolescent Psychiatry34(1), 19–27 (1995).
  • Valleni-Basile LA, Garrison CZ, Jackson KL et al Frequency of obsessive-compulsive disorder in a community sample of young adolescents. jAm. Acad. Child Adolescent Psychiatry 33,782–791 (1994).
  • Rasmussen SA, Eisen JL. The epidemiology and differential diagnosis of obsessive compulsive disorder. J. Clitz P.Tchiatry 55 (Suppl.), 5–14 (1994).
  • Karno MM, Golding JM, Sorenson SB, Burnam MA. The epidemiology of obsessive-compulsive disorder in five US communities. Arrh. Gen. fiychiatry 45, 1094–1099 (1988)
  • Calvocoressi L, Lewis B, Harris M etal Family accommodation in obsessive-compulsive disorder. Am. J. Psychiatry 152, 441 (1995)
  • Rapoport JL, Leonard HL, Swedo SE, Lenane MC. Obsessive compulsive disorder in children and adolescents: Issues in management. j Clin. P4ychiatry54(6 Suppl.), 27–30 (1993).
  • Swedo SE, Rapoport JL, Leonard H, Lenane M, Cheslow D. Obsessive-compulsive disorder in children and adolescents. Arch. Gen. liychiatry46, 335–341 (1989).
  • Greist JH, Jefferson JVV, Kobak Katzelnick DJ, Serlin RC. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch. Gen. Psychiatry52, 53–60 (1995).
  • Hollander E, Kaplan A, Allen A, Cartwright C. Pharmacotherapy for obsessive-compulsive disorder. Psychiatr Clin. N. Am. 23(3), 643–656 (2000).
  • Ananth J. Clomipramine in obsessive- compulsive disorder: a review. PTchosomatics 24,723–727 (1983).
  • Lopez-Ibor JJ. Ensayo clinic° de la monochlorimipramina. Read at the Fourth World Congress of Psychiatry, Madrid, Spain (1966).
  • DeVeaugh-Geiss J, Moroz G, Biederman J etal Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder: A multicenter trial. Am. Acad. Child Adolesc. fiychiatry31, 45–49 (1992).
  • ••Provided finding for the use ofclomipramine specific to children and adolescents.
  • DeVeaugh-Geiss J. Pharmacologic therapy of obsessive compulsive disorder. Adv. Pharmacol 30,35–52 (1994).
  • Rosenberg DR. Tricyclic Antidepressants. In: Pharmacotherapy for child, and adolescent psychiatric disorrlers: second edition, revised and expanded Rosenberg DR, Davanzo P, Gershon S (Eds), Marcel Dekker, New York, USA, 169–222 (2002).
  • •Comprehensive review of TCAs, including clomipramine.
  • VVard HE. The Newer Antidepressants. IM Internal Medicine 18(7), 65–76 (1997).
  • Potter WZ, Calil HM, Sutfin TA etal Active metabolites of imipramine and desipramine in man. Clin. Pharmacol Ther. 31(3), 393–401 (1982).
  • Preskorn SH, Jerovich GS, Beber JH, Widener P. Therapeutic drug monitoring of tricyclic antidepressants: a standard of case issue. fiychopharmacol Bull. 25(2), 281–284 (1989).
  • Preskorn SH, Weller EB, Weller RA, Glotzbach E. Plasma levels of imipramine and adverse effects in children. Am. J. Psychiatry140(10), 1332–1335 (1983).
  • Sjoquist F, Bertilsson L. Clinical pharmacology of antidepressant drugs: pharmacogenetics. Adv. Biochem. Psychopharmacol 39,359–372 (1984).
  • Ryan ND, Puig-Antich J, Cooper TB et al Relative safety of single versus divided dose imipramine in adolescent major depression. Am. Acad. Child Adolesc. Psychiatry26(3), 400–406 (1987).
  • Pigott TA, Seay SM. A review of the efficacy of selective serotonin re-uptake inhibitors in obsessive-compulsive disorder. Clin. Psychiatry60, 101–110 (1999).
  • Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L. Clomipramine treatment of obsessive compulsive disorder: I. A controlled clinical trial. Arch. Gen. Psychiatry37, 1281–1285 (1980).
  • Flament ME, Rapoport JL, Berg CJ et al Clomipramine treatment of childhood obsessive compulsive disorder: A double-blind controlled study. Arch. Gen. Psychiatry 42,977–983 (1985).
  • Cartwright C, Hollander E. SSRIs in the treatment of obsessive-compulsive disorder. Depress. Anxiety 8\(Suppl. 1), 105–113 (1998).
  • Rosenberg DR. Selective Serotonin Re- uptake Inhibitors. In: Pharmacothempy for child, and adolescent psychiatric disorders: second edition, revised and expanded. Rosenberg DR, Davanzo P, Gershon S (Eds), Marcel Dekker, New York, USA, 223–296 (2002).
  • Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, paroxetine and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. Clin. Psychopharmacol 17,267–271 (1997).
  • Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with OCD. Arch. Gen. Psychiatry 48,730–738 (1991).
  • ••Shows support for the efficacy ofclomipramine in OCD patients.
  • March J, Frances A, Kahn D, Carpenter D. Expert Consensus Guidelines: treatment of obsessive-compulsive disorder. J. Clin.PTchiatry 58 (Suppl. 4), 1–72 (1997).
  • ••Provides comprehensive algorithm fortreatment of OCD.
  • Riddle MA, Reeve EA, Yaryura-Tobias JA etal Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. j Am. Acad. Child Adolesc PTchiatry 40,222–229 (2001).
  • March JS, Biederman J, Wolkow R etal Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JA/V/A 280,1752–1756 (1998) .
  • Geller D, Coffey B, Rosenberg D, Carpenter D, Pants D. Recent advances in pediatric obsessive compulsive and Tourette's disorders. Scientific Proceedings of the 4th Annual Meeting of the American Academy of Children and Adolescent PTchiatry31, 68–69 (2001)
  • Geller DA, Carpenter DJ, Biederman J, Wagner K, Emslie G, Carpenter D. Comorbid Psychiatric Illness and Response to Paroxetine in Pediatric OCD. Proceedings of the American Academy of Child and Adolescent Psychiatry Honolulu, HI. October (2001).
  • Geller DA, Hoog SL, Heiligenstein JH etal. Ruoxetine treatment for obsessive-compulsive disorder in children and adolescents: A placebo-controlled clinical trial. jAm. Acad. Child Adolesc. Psychiatry 40(7), 773–779 (2001).
  • Emslie G, Judge R. Tricyclic antidepressants and selective serotonin re-uptake inhibitors: use during pregnancy, in children/adolescents and in the elderly. Acta PTchiatr Scand Suppl 403,26–34 (2000).
  • Riddle MA, Scahill L, King RA eta]. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J. Am. Acad. Child Adolesc. Psychiatry31 (6), 1062–1069 (1992).
  • Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Efficacy of drug treatment in
  • •• obsessive-compulsive disorder: a meta-analytic review. BE J. Psychiatry 166,424-443 (1995).
  • Stein DJ, Spadaccinni E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int. Clin. fiychopharmacol 10,11–18 (1995).
  • Pigott TA, Pato MT, Bernstein SE etal Controlled comparison of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch. Gen. fiychiatry47,926–930 (1990).
  • Smeraldi E, Erzezovesi S, Bianchi I etal. Fluvoxamine venus domipramine treatment in OCD: a preliminary study. New Bends Expo. Gun. Psychiatry8, 63–65 (1992).
  • Freeman CPL, Trimble MR, Deakin JFVV et al Fluvoxamine versus clomipramine in the treatment of obsessive-compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. Clin. Psychopharmacol 55,301–305 (1994).
  • Koran LM, McLeroy Sl, Davidson JRT et al Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J. Gun. Rychopharmacol 16,121–129 (1996).
  • Lopez-Ibor JJ Jr, Saiz J, Cottraux J eta]. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Eur. Neuropsychopharmacol 6(2), 111–118 (1996).
  • Bisserbe JC, Lane RM, Flament ME and the Franco-Belgian OCD Study Group. A double-blind comparison of sertraline and clomipramine in out-patients with obsessive-compulsive disorder. Eur. Psychiatry 12,82–93 (1997).
  • Zohar J, Judge R and the OCD Paroxetine Study Investigators. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. BE j Psychiatry 169, 468–474 (1996).
  • Flament MF, Bisserbe JC. Pharmacologic treatments of obsessive-compulsive disorder: comparative studies. J. Gun. fiychiatry58(12), 18–22 (1997).
  • Cardiac Arrhythmia Pilot Study (CAPS) Investigators. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. Am.j Carrliol 61,501–509 (1988).
  • Baldessarini R. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th. Pergamon Press, New York, USA, 383–435 (1990).
  • Gutgesell H, Atkins D, Barst R eta]. AHA scientific statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J. Am. Acad. Child Adolesc. Psychiatry 38(8), 1047–1050 (1999).
  • Ryan N. Heterocyclic antidepressants in children and adolescents. J. Child Adolesc. fiychopharmacol 1,21–30 (1990).
  • Biederman J, Baldessarini R, Wright V, Knee D, Harmatz J, Goldblatt A. A double-blind placebo-controlled study of desipramine in the treatment of ADD, II: serum drug levels and cardiovascular findings. jAm. Acad. Child Adolesc. fiychiatry28(903), 911 (1989).
  • Schroeder JS, Mullin AV, Elliott GR etal Cardiovascular effects of desipramine in children [see comments]. J. Am. Acad. Child Adolesc. fiychiatry28(3), 376–379 (1989).
  • Fletcher SE, Case CL, Sallee FR, Hand LD, Gillette PC. Prospective study of the electrocardiographic effects of imipramine in children. J. PecliatE 122 (4), 652–654 (1993).
  • Wilens T, Biederman J, Baldessarini R eta]. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. jAm. Acad. Child Adolesc. fiychiatry35, 1491–1501 (1996).
  • Wilens T, Biederman J, Baldessarini R, Puopolo P, Flood J. Electrocardiographic effects of desipramine and 2-hydroxydesipramine in children, adolescents and adults treated with desipramine. j AM Acad. Child Adolesc. fiychiatry32, 798–804 (1993).
  • Geller B, Reising D, Leonard HL, Riddle MA, Walsh BT Critical review of tricyclic antidepressant use in children and adolescents. jAm. Acad. Child Adolesc. fiychiatry38(5), 513–516 (1999).
  • Walsh BT, Giardina EG, Sloan RP, Greenhill L, Goldfein J. Effects of desipramine on autonomic control of the heart. j A117. Acad. Child Adolesc. Psychiatry 33(2), 191–197 (1994).
  • Mezzacappa E, Steingard R, Kindlon D, Saul JP, Earls E Tricyclic antidepressants and cardiac autonomic control in children and adolescents. jAm. Acad. Child Adolesc. Psychiatry37 (1), 52–59 (1998).
  • Dugas M, Zarifian E, Leheuzey ME, Rovei V, Durand G, Morselli PL. Preliminary observations of the significance of monitoring tricyclic antidepressant plasma levels in the pediatric patient. Ther. Drug Monit. 2(4), 307–314 (1980).
  • Koran LM, Sallee FR, Pallanti S. Rapid benefit of iv. pulse loading of clomipramine in obsessive-compulsive disorder. Am. J. Psychiatry 154,396-401 (1997). Provides insight on the benefits of intravenous clomipramine use.
  • Capstick N. Clomipramine in obsessional states. fiychosomatics 12,332–335 (1971).
  • Rack PH. Clomipramine (Anafranil) in the treatment of obsessional states with special reference to the Leyton Obsessional Inventory. J. Int. Med. Res. 1,397–402 (1973).
  • Rack PH. Clinical experience in the treatment of obsessional states, 2.1 Int. Med. Res. 5,81-90 (1977).
  • Ribgy B, Clarren S, Kelly D. A psychological and physiological evaluation of the effects of iv. clomipramine (Anafranil). Int. Med Res. 1,308–316 (1973).
  • Faravelli C, Pallanti S. Clomipramine by different routes of administration: short-and long-term efficacy and predictors of clinical outcome. PTchopharmacol Bull. 23, 459–463 (1987).
  • Walter CS. Clinical impressions of treatment obsessional states with iv. clomipramine (Anafranil). J. Int. Med. Res. 1,413–416 (1973).
  • Fallon BA, Campeas R, Schneier FR etal. Open trial of iv. clomipramine in five treatment-refractory patients with obsessive-compulsive disorder. J. Neurvpsychiatry Clin. Aiurasci. 4,70–75 (1992).
  • Fallon BA, Liebowitz MR, Campeas R et al Intravenous Clomipramine for Obsessive Compulsive Disorder Refractory to Oral Clomipramine. Arch. Gen. Psychiatry 55(10), 918–924 (1998).
  • ••Shows that intravenous clomipramine use can be effective in treatment refractory patients.
  • Koran LM, Faravelli C, Pallanti S. Intravenous clomipramine for obsessive-compulsive disorder. J. Gun. Psychopharmacol 14,216–218 (1994).
  • Warneke LB. Intravenous clomipramine in obsessive-compulsive disorder. Can. J. PFhiatry34, 853–859 (1989).
  • Warneke LB. Intravenous clomipramine in the treatment of obsessional disorder in adolescence: a case report. J. Gun. Psychiatry 46,100–103 (1985).
  • Warneke LB. The use of iv. chlormipramine in the treatment of obsessive compulsive disorder. Can.J.Rychiafry29,135–141 (1984).
  • Mundo E, Bareggi SR, Pirola R, Bellodi L. Effect of acute iv. clomipramine and anti-obsessional response to proserotonergic drugs: is gender a predictive variable? Biol. Psychiatry 45, 290–294 (1999).
  • Mundo E, Bellodi L, Smeraldi E. Effects of acute iv. clomipramine on obsessive-compulsive symptoms and response to chronic treatment. Biol. Psychiatry38,525–531 (1995).
  • Koran LM, Pallanti S, Paiva RS, Quercioli L. Pulse loading versusgradual dosing of iv. clomipramine in obsessive-compulsive disorder. Eur. Neumpsychopharmacol 8(2), 121–126 (1998).
  • •Provides comparison of methods of administration for intravenous clomipramine.
  • Sallee FR, Koran LM, Pallanti S, Carson SW, Sethuraman G. Intravenous clomipramine challenge in obsessive-compulsive disorder: predicting response to oral therapy at eight weeks. Biol. Psychiatry 44(3), 220–227 (1998).
  • Mathew SJ, Coplan JD, Perko IKA etal Neuroendocrine predictors of response to iv. clomipramine therapy for refractory obsessive-compulsive disorder. Depress. Anxiety14(4), 199–208 (2001).
  • King RA, Leonard H, March J. Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J. Am. Acad. Child Adolesc. Psychiatry 37(10), (1998).
  • Franklin ME, Kozak MJ, Cashman LA, Coles ME, Rheingold AA, Foa EB. Cognitive-behavioral treatment of pediatric obsessive-compulsive disorder: an open clinical trial. jAm Acad. Child Adolesc. Psychiatry37, 412–419 (1998).
  • March JS, Mulle K, Herbel B. Behavioral psychotherapy for children and adolescents with obsessive-compulsive disorder: an open trial of a new protocol-driven treatment package. J. Am. Acad. Child Adolesc. Psychiatry 33,333–341 (1994).
  • Weyer C, Rey JM. Juvenile obsessive- compulsive disorder. Aust. NZI. Psychiatry 31,105–113 (1997).
  • Davanzo P. Novel (Atypical) Antidepressants. In: Phalmacotherapy for child, and adolescent psychiatric disorrlers: second edition, revised and expanded. Rosenberg DR, Davanzo P, Gershon S (Eds), Marcel Dekker, New York, USA, 297–316 (2002).

Websites

  • http://medix.marshall.edu/— hisghmal/ appz/medicine/Psychiatric%20Drugs.pdf Albers LJ, Hahn RK, Reist C. Current clinical strategies, handbook of psychiatric drugs 2001–2002 edition.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.